Angina

Data demonstrates long term efficacy of CardioGenesis TMR

Published in Angiogenesis Weekly, February 7th, 2003

CardioGenesis Corp. (CGCP), a company focused on angina-relieving transmyocardial revascularization (TMR) and percutaneous myocardial revascularization (PMR), announced that the first long-term follow-up data of a randomized, controlled TMR clinical trial show that 96% of surviving patients exhibited an improvement (reduction in pain) of at least two angina classes 5 years after their initial TMR treatment.

The data also showed that incremental reductions in pain occurred after 1 year.

Keith B. Allen, MD, a cardiothoracic surgeon at St. Vincent's Hospital in Indianapolis, one of the two centers that have completed long-term follow-up of the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Angiogenesis Weekly

Source: Angiogenesis Weekly (2003-02-07)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry